| Behavioral alterations in autism model induced by valproic acid and translational analysis of circulating microRNA MM Hirsch, I Deckmann, M Fontes-Dutra, G Bauer-Negrini, GDF Nunes, ... Food and Chemical Toxicology 115, 336-343, 2018 | 68 | 2018 |
| Resveratrol prevents cellular and behavioral sensory alterations in the animal model of autism induced by valproic acid M Fontes-Dutra, J Santos-Terra, I Deckmann, G Brum Schwingel, ... Frontiers in Synaptic Neuroscience 10, 9, 2018 | 61 | 2018 |
| Abnormal empathy-like pro-social behaviour in the valproic acid model of autism spectrum disorder M Fontes-Dutra, GDF Nunes, J Santos-Terra, W Souza-Nunes, ... Behavioural brain research 364, 11-18, 2019 | 33 | 2019 |
| Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism MM Hirsch, I Deckmann, J Santos-Terra, GZ Staevie, M Fontes-Dutra, ... Neuropharmacology 167, 107930, 2020 | 31 | 2020 |
| Resveratrol prevents brain edema, blood–brain barrier permeability, and altered aquaporin profile in autism animal model I Deckmann, J Santos‐Terra, M Fontes‐Dutra, M Körbes‐Rockenbach, ... International Journal of Developmental Neuroscience 81 (7), 579-604, 2021 | 23 | 2021 |
| Resveratrol prevents cytoarchitectural and interneuronal alterations in the valproic acid rat model of autism J Santos-Terra, I Deckmann, G Carello-Collar, GDF Nunes, ... International Journal of Molecular Sciences 23 (8), 4075, 2022 | 12 | 2022 |
| Resveratrol prevents cellular and behavioral sensory alterations in the animal model of autism induced by valproic acid. Front Synaptic Neurosci 10: 9 M Fontes-Dutra, J Santos-Terra, I Deckmann, G Brum Schwingel, ... | 9 | 2018 |
| Usability evaluation of circRNA identification tools: Development of a heuristic-based framework and analysis G Bauer-Negrini, GC da Fonseca, C Gottfried, J Herbert Computers in Biology and Medicine 147, 105785, 2022 | 7* | 2022 |
| Reduced CD4 T lymphocytes in lymph nodes of the mouse model of autism induced by valproic acid D Baronio, G Bauer-Negrini, K Castro, G Della-Flora Nunes, R Riesgo, ... Neuroimmunomodulation 25 (5-6), 280-284, 2019 | 5 | 2019 |
| Data on social transmission of food preference in a model of autism induced by valproic acid and translational analysis of circulating microRNA MM Hirsch, I Deckmann, M Fontes-Dutra, G Bauer-Negrini, GDF Nunes, ... Data in brief 18, 1433-1440, 2018 | 5 | 2018 |
| The role of T-cells in neurobehavioural development: Insights from the immunodeficient nude mice G Bauer-Negrini, I Deckmann, GB Schwingel, MM Hirsch, M Fontes-Dutra, ... Behavioural Brain Research 418, 113629, 2022 | 2 | 2022 |
| Classification of Autism Spectrum Disorder using a 3D-CNN ensemble model and regional homogeneity data from the ABIDE I dataset G Bauer-Negrini, LV Lucchese, VR Botelho, TA Pianoschi, CDL Becker Latin American Conference on Biomedical Engineering, 359-370, 2022 | 1 | 2022 |
| Confounding factors to Alzheimers disease plasma biomarkers in patients from a memory-clinic cohort MS Rodrigues, M Oliveira, FZ Lussier, PCL Ferreira, G Bauer-Negrini, ... Alzheimer's Association International Conference, 2024 | | 2024 |
| Exploring the utility of Plasma GFAP as a secondary endpoint in Alzheimer's disease Clinical trials to monitor disease progression. S Abbas, PCL Ferreira, B Bellaver, G Povala, F Rohden, CS Aguzzoli, ... Alzheimer's Association International Conference, 2024 | | 2024 |
| Plasma high-density lipoprotein levels is associated with preserved hippocampal volume in Alzheimers disease individuals without vascular co-pathology MS Rodrigues, MS Oliveira, FZ Lussier, PCL Ferreira, G Povala, ... Alzheimer's Association International Conference, 2024 | | 2024 |
| Utility of plasma p-tau217 as a secondary outcome for clinical trials across AD continuum PCL Ferreira, B Bellaver, G Povala, CS Aguzzoli, JP Ferrari-Souza, ... Alzheimer's Association International Conference, 2024 | | 2024 |
| Hippocampal degeneration is associated with GFAP levels in individuals with vascular dementia independently of amyloidosis. M Oliveira, B Bellaver, FZ Lussier, PCL Ferreira, G Povala, DT Leffa, ... Alzheimer's Association International Conference, 2024 | | 2024 |
| Evaluating Congruence Between Clinical and Biological Staging Across The Alzheimer’s Disease Spectrum H Zalzale, MS Madeiros, C Soares, G Bauer-Negrini, G Povala, ... Alzheimer's Association International Conference, 2024 | | 2024 |
| Attention-deficit/hyperactivity disorder impacts the development of neuropsychiatric symptoms in Alzheimer’s disease DT Leffa, B Bellaver, G Povala, PCL Ferreira, JP Ferrari-Souza, ... Alzheimer's Association International Conference, 2024 | | 2024 |
| Robust Symptomatic Subtypes of Typical Alzheimer's Disease Characterized by Differential Neuropathological Patterns and Functional Decline H Zalzale, PCL Ferreira, P Lemaire, MS Madeiros, C Soares, B Bellaver, ... Alzheimer's Association International Conference, 2024 | | 2024 |
